Literature DB >> 1998795

Study of general practice consultations and menopausal problems. Oxford General Practitioners Menopause Study Group.

D H Barlow1, J A Brockie, C M Rees.   

Abstract

OBJECTIVE: To investigate the nature of work related to the menopause in general practice.
DESIGN: Questionnaire study over six months among general practitioners after each consultation with a woman aged 40-69 at which issues related to the climacteric had been discussed.
SETTING: 9 General practices in the Oxford area.
SUBJECTS: 416 Women who had 572 consultations. MAIN OUTCOME MEASURES: Age, menopausal state, and first or subsequent consultation. Symptoms were classified together with the treatment and the outcome of the consultation.
RESULTS: The consultation rate varied greatly between practices, the overall rate being 4.4%. There were many premenopausal women and women in their 60s presenting; women with hysterectomies presented more often--36% (37/103) of women with hysterectomies had more than one consultation compared with 26% (38/144) for premenopausal women and 24% (38/155) for postmenopausal women. 409 women had symptoms and 218 were prescribed oestrogen treatment. 156 of the consultations involved discussion and advice only. Only four women were referred to a local specialist clinic.
CONCLUSION: There is a low overall use of hormone replacement therapy in the general postmenopausal population despite the recent media coverage of its benefits in the prevention of osteoporosis and subsequent fractures.

Entities:  

Mesh:

Year:  1991        PMID: 1998795      PMCID: PMC1668919          DOI: 10.1136/bmj.302.6771.274

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  10 in total

1.  A study of the experience of Glasgow women in the climacteric years.

Authors:  D H Barlow; K A Grosset; H Hart; D M Hart
Journal:  Br J Obstet Gynaecol       Date:  1989-10

Review 2.  Hormone replacement treatment.

Authors:  P Belchetz
Journal:  BMJ       Date:  1989-06-03

3.  Use of oestrogen replacement therapy in high risk groups in the United Kingdom.

Authors:  T D Spector
Journal:  BMJ       Date:  1989-12-09

4.  Brighton practitioners' attitudes to HRT.

Authors:  M R Shears
Journal:  Practitioner       Date:  1989-02-08

5.  Menopausal age and symptomatology in a general practice.

Authors:  B Thompson; S A Hart; D Durno
Journal:  J Biosoc Sci       Date:  1973-01

6.  Negative affect, alcohol consumption and hangover symptoms among normal drinkers in a small community.

Authors:  E Harburg; D Davis; K M Cummings; R Gunn
Journal:  J Stud Alcohol       Date:  1981-11

7.  Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis.

Authors:  J Draper; M Roland
Journal:  BMJ       Date:  1990-03-24

8.  Psychiatric morbidity and the menopause; screening of general population sample.

Authors:  C B Ballinger
Journal:  Br Med J       Date:  1975-08-09

9.  Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy.

Authors:  J M Aitken; D M Hart; R Lindsay
Journal:  Br Med J       Date:  1973-09-08

10.  Hangover headache and prostaglandins: prophylactic treatment with tolfenamic acid.

Authors:  S Kaivola; J Parantainen; T Osterman; H Timonen
Journal:  Cephalalgia       Date:  1983-03       Impact factor: 6.292

  10 in total
  4 in total

1.  Osteoporosis--an opportunity to prevent being missed.

Authors:  A D Woolf
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

2.  Hormone replacement therapy.

Authors:  P J Roberts
Journal:  Br J Gen Pract       Date:  1995-10       Impact factor: 5.386

3.  Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995.

Authors:  M T Connelly; M Richardson; R Platt
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

4.  The menopause and hormone replacement therapy: views of women in general practice receiving hormone replacement therapy.

Authors:  P J Roberts
Journal:  Br J Gen Pract       Date:  1991-10       Impact factor: 5.386

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.